Chemistry:Robalzotan

From HandWiki
Short description: Chemical compound
Robalzotan
Robalzotan 1.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC18H23FN2O2
Molar mass318.392 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT1A receptor.[1] It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like citalopram in rodent studies.[2] It was subsequently investigated by AstraZeneca as a potential antidepressant but like many other 5-HT1A ligands was discontinued.[3] Later on it was researched for other indications such as irritable bowel syndrome but was dropped once again.[4]

See also

References

  1. "Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist.". Eur J Pharmacol 360 (2–3): 219–225. 1998. doi:10.1016/S0014-2999(98)00667-0. PMID 9851589. 
  2. "The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing.". Eur J Pharmacol 382 (2): 133–138. 1999. doi:10.1016/S0014-2999(99)00592-0. PMID 10528148. 
  3. Mucke HA. (2000). "Robalzotan AstraZeneca.". Curr Opin Investig Drugs 1 (2): 236–240. PMID 11249580. 
  4. "Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome". The American Journal of Gastroenterology 103 (10): 2562–9. October 2008. doi:10.1111/j.1572-0241.2008.02115.x. PMID 18775020.